GSK plc has agreed with the U.S. government to lower drug prices and expand access to respiratory medicines for over 40 million Americans, effective immediately as of December 19, 2025, enhancing affordability and availability of these critical medications. Additionally, GSK plans to invest over $30 billion in R&D and manufacturing in the U.S. over the next five years, creating hundreds of skilled jobs and securing a reserve of essential medicines.